ABSTRACT
Background The COVID-19 pandemic presented an unprecedented challenge to identify effective drugs for prevention and treatment.
Objective To characterize acute renal injury (AKI) in patients with COVID-19 and their relation with clinical outcomes within the framework of the SENTAD COVID clinical trial at the Abu Dhabi Stem Cells Center.
Methods Abu Dhabi Stem Cell Center (ADSCC) proposed a prospective clinical trial nebulization treatment with autologous stem cells (Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)), at Abu Dhabi hospitals.
Participants 20 treated patients were compared with 23 not treated patients. Both groups received COVID 19 standard treatment.
Outcomes After the results were collected, this study was created to determine the impact of the disease on the renal function and the efficacy of the therapy on patient’s outcomes.
Results One third of the critical patients studied suffered kidney failure. Patients in the treated group showed a favorable tendency to improve in contrast to those in the control group. Less patients from group A suffered from sepsis in comparison with the group B (25% vs 65%), HR=0.38, (95% Confidence Interval: 0.16 – 0.86), *p=0.0212. These results suggested a NNT=2.5. An improvement in lymphocyte count, CRP, and shorter hospital stay after treatment was evidenced, which led to less superinfection and sepsis in the treated group.
Conclusions The proposed anti-inflammatory effect of the stem cells, offers a great promise for managing the illness, emerging as a crucial adjuvant tool in promoting healing and early recovery in severe COVID-19 infections and other supportive treatments.
ARTICLE SUMMARY Our study had several strengths and limitation:
It was a randomized trial.
The treatment showed a positive result, providing evidence that this intervention is effective in routine practice.
We found fewer complications related to prolonged hospital stay in the treated group.
The is the small number of participants.
It was carried out in 4 different hospitals, each with different criteria for the selection of the initial empirical antimicrobials, which can cause multiple resistant germs.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04473170
Funding Statement
This work was supported by ADSCC. This research had not received any other specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Emirates Institutional Review Board for COVID-19 Research (Ref. ID: DOH/CVDC/2020/1172)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
All authors participated on the critical revision of the manuscript for important intellectual content
Mailing address: Street #31, Area Muroor Road, Building # C43, Al Murjan Tower, Apartment 107, Abu Dhabi, UAE.
Abu Dhabi Stem Cells Center (ADSCC) Ringgold ID: 580443.
Data Availability
Extra data is available by emailing dr.torresz{at}gmail.com.
